Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07519655). This is a study registration, not published results. Lead sponsor: Pfizer. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 250 participants (ESTIMATED). Conditions: Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma. Interventions: DRUG: PF-08046033. Primary outcome measures: Type, incidence and severity of participants with adverse events (AEs) , From the first day through 30-37 days after the last study treatment, up to approximately 1 year; Type, incidence, and severity of participants with laboratory abnormalities , From the first day through 30-37 days after the last study treatment, up to approximately 1 year; Number of participants with dose modifications , From the first day through 30-37 days after the last study treatment, up to approximately 1 year; Incidence of dose-limiting toxicities (DLTs) , From the first day through 30-37 days after the last study treatment, up to approximately 1 year; Recommended dose and schedule of PF-08046033 for expansion (RDE) , Up to 1 year. Brief summary: This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer. The study includes adult participants who have advanced cancers that cannot be removed by surgery or have spread to other parts of the body. These cancers include non-small cell lung cancer, esophageal squamous cell cancer, and melanoma. The study has two parts: In the first part, small groups of participants receive increasing doses of the study medicine. This helps researchers find a dose that is safe and suitable for further testing. Once a suitable dose is identified, the second part enrolls more participants with specific cancer types to better understand the safety of the medicine and whether it shows signs of helping control the cancer. Participants receive the study medicine through regular treatment cycles and are closely monitored for side effects and how their cancer responds. The information from this study will help researchers decide whether PF-08046033 should be studied further in later-stage clinical trials.